Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific An
Go back to Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific An| (NASDAQ: ACRS) | Delayed: 4.79 -0.13 (2.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.92 | 52 Week High | $33.88 | |||
| Open | $4.93 | 52 Week Low | $14.12 | |||
| Day High | $5.00 | P/E | N/A | |||
| Day Low | $4.71 | EPS | $0.00 | |||
| Volume | 1,482,355 | |||||
